1. McIntyre H.D., Catalano P., Zhang C., Desoye G., Mathiesen E.R., Damm P.: Gestational diabetes mellitus. Nat Rev Dis Primers. 2019; 5: 47. JAMA 1967; 200: 1129–1131.
2. Lowe L.P., Metzger B.E., Dyer A.R., et al.: Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations of maternal A1C and glucose with pregnancy outcomes. Diabetes Care. 2012; 35: 574–580.
3. Gortazar L., Flores-Le Roux J.A., Benaiges D., et al.: Trends in prevalence of gestational diabetes and perinatal outcomes in Catalonia, Spain, 2006 to 2015: the Diagestcat Study. Diabetes Metab Res Rev. 2019; 35: e3151.
4. Cade T.J., Polyakov A., Brennecke S.P.: Implications of the introduction of new criteria for the diagnosis of gestational diabetes: a health outcome and cost of care analysis. BMJ Open. 2019; 9: e023293.
5. Mack L.R., Tomich P.G.: Gestational Diabetes: Diagnosis, Classification and Clinical Care. Obstet. Gynecol. Clin. North Am. 2017; 44: 207–217.
6. Egan A.M., Vellinga A., Harreiter J., et al.: Epidemiology of gestational diabetes mellitus according to IADPSG/WHO 2013 criteria among obese pregnant women in Europe. Diabetologia. 2017; 60: 1913– 1921.
7. Lean S.C., Derricott H., Jones R.L., et al.: Advanced maternal age and adverse pregnancy outcomes: A systematic review and meta-analysis. PLoS One. 2017; 12: e0186287.
8. Chiefari E., Arcidiacono B., Foti D., et al.: Gestational diabetes mellitus: an updated overview. J Endocrinol Invest. 2017; 40:.899–909.
9. Skupień J., Cyganek K., Małecki M.T.: Diabetic pregnancy: an overview of current guidelines and clinical practice. Curr Opin Obstet Gynecol. 2014; 26: 431–417.
10. Behboudi-Gandevani S., Amiri M., Bidhendi Yarandi R., et al.: The impact of diagnostic criteria for gestational diabetes on its prevalence: a systematic review and meta-analysis. Diabetol Metab Syndr. 2019; 11: 11.
11. HAPO Study Cooperative Research Group, Metzger B.E., Lowe L.P., et al.: Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008; 358: 1991–2002.
12. World Health Organization: Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization guideline. Diabetes Res Clin Pract. 2014; 103: 341–363.
13. 2020 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clinical Diabetology, supplement A, 2014.
14. Rybińska A.: Motherhood after the age of 35 in Poland. Studia Demogr. 2014; 1: 7–15.
15. Molina-García L., Hidalgo-Ruiz M., Cocera-Ruíz E.M., et al.: The delay of motherhood: Reasons, determinants, time used to achieve pregnancy, and maternal anxiety level. PLoS One. 2019; 14: e0227063.
16. Matthews T.J., Hamilton B.E.: First births to older women continue to rise. NCHS Data Brief. 2014; 152: 1–8.
17. Hammarberg K., Clarke V.E.: Reasons for delaying childbearing — a survey of women aged over 35 years seeking assisted reproductive technology. Aust Fam Physician. 2005; 34 (3): 187–206.
18. Kim M., Park J., Kim S.H., et al.: The trends and risk factors to predict adverse outcomes in gestational diabetes mellitus: a 10-year experience from 2006 to 2015 in a single tertiary center. Obstet Gynecol Sci. 2018; 61: 309–318.
19. Wender-Ożegowska E., Bomba-Opoń D., Brązert J., et al.: The Polish Society of Gynaecologists and Obstetricians standards for the management of patients with diabetes. Ginekologia i Perinatologia Praktyczna. 2017; 2: 215–229.
20. Egan A.M., Dunne F.P.: Epidemiology of Gestational and Pregestational Diabetes Mellitus. In: Lapolla A., Metzger B.E. (eds.): Gestational Diabetes. A Decade after the HAPO Study. Front Diabetes. Basel, Karger, 2020; 28: 1–10.
21. Egan A.M., Dennedy M.C., Al-Ramli W., et al.: ATLANTIC-DIP: excessive gestational weight gain and pregnancy outcomes in women with gestational or pregestational diabetes mellitus. J Clin Endocrinol Metab. 2014; 99: 212–219.
22. Ferreira L.A.P., Piccinato C.A., Cordioli E., et al.: Pregestational body mass index, weight gain during pregnancy and perinatal outcome: a retrospective descriptive study. Einstein (Sao Paulo). 2019; 18: eAO4851.
23. Brown J., Kapurubandara S., McGee T.M.: Confounding effect of ethnic diversity on booking-in body mass index and prevalence of gestational diabetes and hypertensive disorders in pregnant women in western Sydney 1997–2016. Aust N Z J Obstet Gynaecol. 2020; 60: 369–375.
24. Lavery J.A., Friedman A.M., Keyes K.M., et al.: Gestational diabetes in the United States: temporal changes in prevalence rates between 1979 and 2010. BJOG. 2017; 124: 804–813.
25. Fitzpatrick K.E., Tuffnell D., Kurinczuk J.J., et al.: Pregnancy at very advanced maternal age: a UK population-based cohort study. BJOG. 2017; 124: 1097–1106.

Ahangarpour A, Oroojan AA, Khorsandi L, Kouchak M, Badavi M (2018) Antioxidant effect of myricitrin on hyperglycemia-induced oxida-tive stress in C2C12 cell. Cell Stress Chaperones 23: 773-781.

Arora A, Dey CS (2014) SIRT2 negatively regulates insulin resistance in C2C12 skeletal muscle cells. Biochim Biophys Acta 1842: 1372-1378.

Ban N, Ozawa Y, Inaba T, Miyake S, Watanabe M, Shinmura K, Tsubota K (2013) Light-dark condition regulates sirtuin mRNA levels in the retina. Exp Gerontol 48: 1212-1217.

Buranasin P, Mizutani K, Iwasaki K, Pawaputanon Na, Mahasarakham C, Kido D, Takeda K, Izumi Y (2018) High glucose-induced oxidative stress impairs proliferation and migration of human gingival fibroblasts. PLoS One 13: e0201855.

Chang HC, Guarente L (2014) SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab 25: 138-145.

Chao SC, Chen YJ, Huang KH, Kuo KL, Yang TH, Huang KY, Wang CC, Tang CH, Yang RS, Liu SH (2017) Induction of sirtuin-1 sig-naling by resveratrol induces human chondrosarcoma cell apoptosis and exhibits antitumor activity. Sci Rep 7: 3180.

Chen Y, Fu LL, Wen X, Wang XY, Liu J, Cheng Y, Huang J (2014) Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tu-mor-suppressive function in cancer. Cell Death Dis 5: e1047.

Doktorova TY, Ellinger-Ziegelbauer H, Vinken M, Vanhaecke T, van Delft J, Kleinjans J, Ahr HJ, Rogiers V (2012) Comparison of geno-toxicant-modified transcriptomic responses in conventional and epigenetically stabilized primary rat hepatocytes with in vivo rat liver data. Arch Toxicol 86: 1703-1715.

Felice F, Lucchesi D, di Stefano R, Barsotti MC, Storti E, Penno G, Balbarini A, Prato SD, Pucci L (2010) Oxidative stress in response to high glucose levels in endothelial cells and in endothelial progenitor cells: evidence for differential glutathione peroxidase-1 expression. Micro-vasc Res 80: 332-338.

Galban VD, Evangelista EA, Migliorini RH, do Carmo Kettelhut I (2001) Role of ubiquitin-proteasome-dependent proteolytic process in degradation of muscle protein from diabetic rabbits. Mol Cell Biochem 225: 35-41.

Hirata Y, Nomura K, Senga Y, Okada Y, Kobayashi K, Okamoto S, Minokoshi Y, Imamura M, Takeda S, Hosooka T, Ogawa W (2019) Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis. JCI Insight 4: e124952.

Linxi Z, Guirong Z, Xue W, Gang S (2015) The Effect of high glucose on proliferation and expression of correlation factors of MG63 osteo-blasts. J Hard Tissue Biol 24: 143-146.

Liu L, Arun A, Ellis L, Peritore C, Donmez G (2014) SIRT2 enhances 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via apoptotic pathway. Front Aging Neurosci 6: 184.

Liu M, Wilk SA, Wang A, Zhou L, Wang RH, Ogawa W, Deng C, Dong LQ, Liu F (2010) Resveratrol inhibits mTOR signaling by promot-ing the interaction between mTOR and DEPTOR. J Biol Chem 285: 36387-36394.

Luo M, Liu Z, Hao H, Lu T, Chen M, Lei M, Verfaillie CM, Liu Z (2012) High glucose facilitates cell cycle arrest of rat bone marrow mul-tipotent adult progenitor cells through transforming growth factor-β1 and extracellular signal-regulated kinase 1/2 signalling without changing Oct4 expression. Clin Exp Pharmacol Physiol 39: 843-851.

Luo W, Ai L, Wang BF, Zhou Y (2019) High glucose inhibits myogenesis and induces insulin resistance by down-regulating AKT signaling. Biomed Pharmacother 120: 109498.

Orimo M, Minamino T, Miyauchi H, Tateno K, Okada S, Moriya J, Komuro I (2009) Protective role of SIRT1 in diabetic vascular dysfunc-tion. Arterioscler Thromb Vasc Biol 29: 889-894.

Park SH, Choi HJ, Lee JH, Woo CH, Kim JH, Han HJ (2001) High glucose inhibits renal proximal tubule cell proliferation and involves PKC, oxidative stress, and TGF-β1. Kidney Int 59: 1695-1705.

Porreca I, D’Angelo F, De Franceschi L, Mattè A, Ceccarelli M, Iolascon A, Zamò A, Russo F, Ravo M, Tarallo R, Scarfò M, Weisz A, De Felice M, Mallardo M, Ambrosino C (2016) Pesticide toxicogenomics across scales: in vitro transcriptome predicts mechanisms and outcomes of exposure in vivo. Sci Rep 6: 38131.

Quinn ME, Goh Q, Kurosaka M, Gamage DG, Petrany MJ, Prasad V, Millay DP (2017) Myomerger induces fusion of non-fusogenic cells and is required for skeletal muscle development. Nat Commun 8: 15665.

Rathbone CR, Booth FW, Lees SJ (2009) Sirt1 increases skeletal muscle precursor cell proliferation. Eur J Cell Biol 88: 35-44.

Reddy SS, Shruthi K, Joy D, Reddy GB (2019) 4-PBA prevents diabetic muscle atrophy in rats by modulating ER stress response and ubiq-uitin-proteasome system. Chem Biol Interact 306: 70-77.

Samant SA, Kanwal A, Pillai VB, Bao R, Gupta MP (2017) The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy. Sci Rep 7: 11877.

Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399-412.

Schartner E, Sabbir MG, Saleh A, Silva RV, Chowdhury SR, Smith DR, Fernyhough P (2018) High glucose concentration suppresses a SIRT2 regulated pathway that enhances neurite outgrowth in cultured adult sensory neurons. Exp Neurol 309: 134-147.

Sharples AP, Hughes DC, Deane CS, Saini A, Selman C, Stewart CE (2015) Longevity and skeletal muscle mass: the role of IGF signalling, the sirtuins, dietary restriction and protein intake. Aging Cell 14: 511-523.

Shi JX, Wang QJ, Li H, Huang Q (2017) SIRT4 overexpression protects against diabetic nephropathy by inhibiting podocyte apoptosis. Exp Ther Med 13: 342-348.

Surinlert P, Kongthong N, Watthanard M, Sae-lao T, Sookbangnop P, Pholpramool C, Tipbunjong C (2020) Styrene oxide caused cell cycle arrest and abolished myogenic differentiation of C2C12 myoblasts. J Toxicol 2020: 1807126.

Vakhrusheva O, Smolka C, Gajawada P, Kostin S, Boettger T, Kubin T, Braun T. Bober E (2008) Sirt7 increases stress resistance of cardio-myocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res 102: 703-710.

Verdin E, Hirschey MD, Finley LW, Haigis MC (2010) Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci 35: 669-675.

Wang F, Nguyen M, Qin XF, Tong Q (2007) SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell 6: 505–514.

Wang S, Wang J, Zhao A, Li J (2017) SIRT1 activation inhibits hyperglycemia-induced apoptosis by reducing oxidative stress and mitochon-drial dysfunction in human endothelial cells. Mol Med Rep 16: 3331-3338.

Wang X, Hu Z, Hu J, Du J, Mitch WE (2006) Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 147: 4160-4168.

Wronska A, Lawniczak A, Wierzbicki PM, Kmiec Z (2016) Age-related changes in sirtuin 7 expression in calorie-restricted and refed rats. Gerontology 62: 304-310.

Zhang HH, Ma XJ, Wu LN, Zhao YY, Zhang PY, Zhang YH, Shao MW, Liu F, Li F, Qin GJ (2015) SIRT1 attenuates high glucose-induced insulin resistance via reducing mitochondrial dysfunction in skeletal muscle cells. Exp Biol Med (Maywood) 240: 557-565.